NVS - Novartis AG
| Previous Close | 83.15 |
| Open | 84.49 |
| Bid | 0.00 x 1300 |
| Ask | 0.00 x 3200 |
| Day's Range | 84.32 - 85.81 |
| 52 Week Range | 72.30 - 94.19 |
| Volume | 2,827,113 |
| Avg. Volume | 1,808,276 |
| Market Cap | 198.721B |
| Beta (3Y Monthly) | 0.86 |
| PE Ratio (TTM) | 14.57 |
| EPS (TTM) | 5.88 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.98 (3.60%) |
| Ex-Dividend Date | 2018-03-06 |
| 1y Target Est | 98.50 |
- TheStreet.com•12 hours ago
Tesla Jumps After Judge Makes SEC Settlement Official: LIVE MARKETS BLOG
is now official after U.S. District Judge Alison Nathan signed the settlement in Manhattan, Tuesday, Oct. 16. As part of the settlement, Musk will have to step down as chairman of the electric vehicle company and will have to personally pay a $20 million fine in addition to a separate $20 million fine levied against Tesla. The court action comes in the wake of a tweet Musk sent on Aug. 7, suggesting that he had secured enough funding to take the company private at $420 a share.
- Benzinga•15 hours ago
Benchmark Out Bullish On 'Well-Positioned' Tilray Ahead of Canada's Cannabis Legalization
Shares of Tilray Inc. (NASDAQ: TLRY ) surged Monday in anticipation of Canada’s legalization of recreational marijuana. The Analyst Benchmark analyst Mike Hickey initiated coverage of Tilray with a Buy ...
- TheStreet.com•15 hours ago
Tilray Jumps After $200 Price Target and Bullish Rating at Benchmark
The rating is based on an analysts' view that Wednesday's full legalization of cannabis in Canada will be a boon for the company.
- Zacks•16 hours ago
Roche Announces Positive Data on Breast Cancer Drug Kadcyla
Roche's (RHHBY) breast cancer drug Kadcyla, in a late-stage study in patients suffering from HER2-positive eBCmet, met its goal.
- Reuters•17 hours ago
Amgen, Novartis kick off fight for AbbVie blockbuster drug in EU
Rival versions of the world’s top-selling drug, AbbVie's Humira, went on sale in Europe on Tuesday, years ahead of similar cut-price copies being available in the United States. Amgen is rolling out its so-called biosimilar form of Humira, branded as Amgevita, across Europe from Oct. 16, while Novartis said its Sandoz unit was launching its product Hyrimoz initially in Britain, with other markets set to follow. Large sums are at stake, since Humira clocked up worldwide sales of $18 billion last year, of which around $4 billion came from Europe, and European healthcare administrators are eager to exploit the competitive situation to drive down drug bills.
- MarketWatch•17 hours ago
Tilray's stock surges after Benchmark starts coverage with bullish rating, $200 target
Shares of Tilray Inc. shot up 5.7% in premarket trade Tuesday, after Benchmark analyst Mike Hickey started coverage of the Canada-based medical cannabis and cannabinoid company with a buy rating and $200 price target. Hickey's price target is 21% above Monday's closing price $165.64. Hickey said his bullish view is based on the company's early leadership in the medical cannabis market in Canada, the upcoming full legalization of recreational marijuana in Canada and its strategic alliance with Novartis AG and supply agreements with Canadian pharmacies, international growth opportunities and a "meaningful" capital infusion from its initial public offering in July. "We believe establishing an early first mover advantage is critically important in the emerging cannabis market, particularly when it comes to building national and global scale, leading brands, and developing innovative products and form factors that use cannabis as an active ingredient," Hickey wrote in a note to clients. The stock has rocketed more than 7-fold since closing at $22.39 on its first day listed on the Nasdaq on July 19, while the ETFMG Alternative Harvest ETF has run up 55% and the S&P 500 has lost 1.9% over the same time.
- Market Realist•2 days ago
Novartis’ Estimates and Recommendations on October 12
Wall Street analysts estimate that Novartis (NVS) will report revenues of $13.02 billion for the third quarter of 2018, a 4.9% growth year-over-year compared to $12.41 billion. Novartis stock has decreased ~4.9% over the last 12 months. As of October 12, there are two analysts tracking Novartis ADR (American Depositary Receipts).
- Market Realist•2 days ago
Novartis in Q3 2018: Analysts Expect Revenue Growth
Analysts expect Novartis’s revenues to increase ~4.9% to $13.02 billion in the third quarter of 2018. There has been operating revenue growth for all three of its segments in the quarter. Analysts expect Novartis’s Innovative Medicines segment to report revenue growth in the third quarter of 2018 compared to the third quarter of 2017.
- Market Realist•2 days ago
Novartis: What to Expect from Q3 Earnings on October 18
Novartis (NVS) is set to release its third quarter of 2018 earnings results on October 18. Analysts are estimating EPS of $1.31 and revenues of $13.02 billion. Novartis, one of the largest pharmaceutical companies by revenue, specializes in the development, manufacturing, and marketing of healthcare products.
Market Realist•2 days agoAn Update on Bausch + Lomb/International in October
Bausch + Lomb/International, a subsidiary of Bausch Health (BHC), generated net revenues of $1.21 billion in the second quarter, compared to $1.22 billion in the second quarter of 2017. This increase reflects ~4.0% YoY (year-over-year) organic growth.
GuruFocus.com•4 days agoAbbVie Permits US Sale of Sandoz's Humira Biosimilar
The license will take effect on Sept. 30, 2023
- Zacks•5 days ago
Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal
AbbVie (ABBV) signs licensing deal with Sandoz, the generic arm of Novartis. J&J (JNJ) gains FDA approval for label expansion of its blood thinner, Xarelto.
- Zacks•5 days ago
AbbVie Settles With Novartis to Delay Humira Biosimilar in US
AbbVie (ABBV) strikes a deal with Sandoz, the generic arm of Novartis, to launch its biosimilar Humira in the United States on Sep 30, 2023.
Reuters•5 days agoAbbvie settles Humira patent disputes with Novartis unit
Abbvie, however, did not disclose details regarding the royalties it will receive from Novartis generics unit, Sandoz, as part of the agreement. Shares of Abbvie rose 2.39 percent to $92.87 in after-market trading.
- Reuters•5 days ago
Abbvie settles Humira patent disputes with Novartis unit
Abbvie, however, did not disclose details regarding the royalties it will receive from Novartis generics unit, Sandoz, as part of the agreement. Shares of Abbvie rose 2.39 percent to $92.87 in after-market trading.
- MarketWatch•5 days ago
AbbVie stock ticks higher as Humira patent dispute with Novartis resolved
AbbVie Inc. shares ticked higher in the extended session Thursday after the drug maker said it had settled patent disputes with Novartis AG unit Sandoz involving a popular arthritis treatment. AbbVie shares rose 2.4% after hours, following a 2.6% decline to close at $90.70 Thursday. Under an agreement, Sandoz will pay AbbVie royalties of an undisclosed amount for a non-exclusive license of patents for AbbVie's drug Humira, the companies said. Sandoz markets a biosimilar product called Hyrimoz. The license for sale in most European countries will be Oct. 16, while the license for U.S. sales will not start until Sept. 30, 2023.
Market Realist•5 days agoWall Street Analysts See Upside Potential of 3.9% in TEVA
Teva Pharmaceutical Industries (TEVA) is gradually recovering from the lows it witnessed in late 2017 due to generics competition, pricing pressure, and declining Copaxone sales. Teva’s growth prospects have been boosted by the FDA’s recent approval of its migraine drug. In recent months, analysts have been more confident about the company’s growth prospects. As of October 11, 24 analysts covered Teva stock and were included in a recent Reuters survey.
- Zacks•6 days ago
Novartis Presents Data on Multiple Sclerosis Drug Gilenya
Novartis (NVS) announces encouraging data from a late-stage trial, ASSESS, on multiple sclerosis drug, Gilenya, which further reinforces its efficacy in treating relapses.
- Market Realist•6 days ago
Analysts’ Estimates and Ratings for Novartis in October
Novartis’s (NVS) revenue is mainly driven by the strong performance of its Innovative Medicines segment, while Sandoz and Alcon also contribute to the company’s overall growth.
- Market Realist•6 days ago
A Look at the Performance of Novartis’s Alcon
Alcon reported revenue of ~$1.82 billion in the second quarter, a 7% rise including the 5% increase in its operating revenue and the 2% favorable impact of foreign exchange. Alcon announced in September 2018 that it would be locating its future headquarters in Geneva, Switzerland, following the completion of the proposed spinoff from Novartis.
Market Realist•6 days agoCould Johnson & Johnson Meet Its Q3 2018 Sales Estimates?
Johnson & Johnson (JNJ) plans to announce its third-quarter earnings on October 16. According to Reuters estimates, the company is expected to register sales of $20.03 billion. This estimate represents YoY (year-over-year) sales growth of ~1.9%.
- Zacks•6 days ago
Novartis Presents Positive Data on Sickle Cell Disease Drug
Novartis (NVS) announces positive results from a post hoc analysis of the phase II study, SUSTAIN, on pipeline candidate, crizanlizumab, being published in the American Journal of Hematology.
Market Realist•6 days agoAnalysts’ Ratings for Johnson & Johnson before Its Q3 Earnings
What to Expect from Johnson & Johnson's Q3 2018 EarningsAnalysts’ views on Johnson & Johnson
Market Realist•7 days agoCelgene: Multiple Myeloma Franchise Could Drive Growth
How's Celgene Positioned before Its Third-Quarter Earnings? Celgene’s (CELG) hematology and oncology franchise consists of Revlimid, Pomalyst, Abraxane, Idhifa, Vidaza, Istodax, and Thalomid. Revlimid’s revenues grew from $3.9 billion in the first half of 2017 to $4.7 billion in the first half of 2018, which reflects ~19.6% growth YoY (year-over-year).
- Market Realist•7 days ago
How Novartis’s Sandoz Business Has Been Performing Recently
Sandoz reported nearly flat revenue of ~$2.46 billion in the second quarter driven by a 2% favorable impact of foreign exchange and offset by a 2% fall in operating revenue in the quarter. The segment’s biopharmaceuticals portfolio reported revenue of $363 million in the second quarter, a 34% rise in operating revenue driven by an increase in US and European sales following the increased demand of the drugs Omnitrope and Zarxio in US markets and Erelzi and Rixathon in European markets.
